Barrett esophagus: Perspectives on its diagnosis and management in Asian populations

Gastroenterology and Hepatology

Volumn 4, Issue 1, 2008, Pages 45-53

  Amano, Yuji ^a   Kinoshita, Yoshikazu ^b,c  

^a SHIMANE UNIVERSITY HOSPITAL   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

^c Department of Gastroenterology and Hepatology ^*

Author keywords

Asian population; Barrett esophagus; Endoscopic diagnosis; Helicobacter pylori infection

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; PROTON PUMP INHIBITOR;

ASIA; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARCINOGENESIS; ESOPHAGOSCOPY; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIATUS HERNIA; HISTOPATHOLOGY; HUMAN; LOWER ESOPHAGUS SPHINCTER; MORBIDITY; PREVALENCE; RACE DIFFERENCE; REVIEW;

EID: 39749149236     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:1028-1032.
2. Watson A, Heading RC, Shepherd NA, eds. Guidelines for the diagnosis and management of Barrett columnar-lined oesophagus. A report of the working party of the British Society of Gastroenterology. British Society of Gastroenterology [web page]. August 2005. Available at http://www.bsg.org. uk/pdf_word_docs/Barretts_Oes.pdf. Accessed December 10, 2007.
3. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA. 1993;270:1320.
4. Guillem P, Billeret V, Buisine MP, Flejou JF, Lecomte-Houcke M, et al. Mucin expression and cell differentiation in human normal, premalignant, and malignant esophagus. Int J Cancer. 2000;88:856-861.
5. Warson C, Van De Bovenkamp JH, Korteland-Van Male AM, Büller HA, Einerhand AW, et al. Barrett esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) and TFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum Pathol. 2002;33:660-668.
6. Amano Y, Ishihara S, Kushiyama Y, Yuki T, Takahashi Y, et al. Barrett oesophagus with predominant intestinal metaplasia correlates with superficial cyclooxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. Aliment Pharmacol Ther. 2004;20:793-802.
7. Amano Y, Kushiyama Y, Yuki T, Takahashi Y, Moriyama I, et al. Prevalence of and risk factors for Barrett esophagus with intestinal predominant mucin phenotype. Scand J Gastroenterol. 2006;41:873-879.
8. Hongo M, Shoji T. Epidemiology of reflux disease and CLE in East Asia. J Gastroenterol. 2003;38(suppl 15):25-30.
9. Schnell TG, Sontag SJ, Chejfec G. Adenocarcinoma arising in tongues or short segments of Barrett esophagus. Dig Dis Sci. 1992;37:137-143.
10. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol. 1997;92:212-215.
11. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett esophagus: a prospective 3-year follow-up. Am J Gastroenterol. 1997;92:2012-2016.
12. Yeh C, Hsu CT, Ho AS, Sampliner RE, Fass R. Erosive esophagitis and Barrett esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci. 1997;42: 702-706.
13. Chen PH. Review: Barrett oesophagus in Taiwan. J Gastroenterol Hepatol. 1997; 12:S19-22.
14. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol. 1996;91:1507-1511.
15. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999;116:277-285.
16. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461-467.
17. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, et al. Screening for Barrett esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670-1677.
18. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, et al. Prevalence of Barrett esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-1831.
19. Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, et al. Barrett esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006;101:12-17.
20. Romero Y, Cameron AJ, Schaid DJ, McDonnell SK, Burgart LJ, et al. Barrett esophagus: prevalence in symptomatic relatives. Am J Gastroenterol. 2002;97: 1127-1132.
21. Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc. 2005;61:226-231.
22. Cameron AJ, Lomboy CT. Barrett esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology. 1992;103:1241-1245.
23. Rajendra S, Kutty K, Karim N. Ethnic differences in the prevalence of endoscopic esophagitis and Barrett esophagus: the long and short of it all. Dig Dis Sci. 2004;49:237-242.
24. Wong WM, Lam SK, Hui WM, Lai KC, Chan CK, et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese: prevalence and spectrum of the disease. Aliment Pharmacol Ther. 2002;16:2037-2042.
25. Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Barrett esophagus and its correlation with gastroesophageal reflux in Chinese. World J Gastroenterol. 2004;10:1065-1068.
26. Amarapurkar AD, Vora IM, Dhawan PS. Barrett esophagus. Indian J Pathol Microbiol. 1998;41:431-435.
27. Dhawan PS, Alvares JF, Vora IM, Joseph TK, Bhatia SJ, et al. Prevalence of short segments of specialized columnar epithelium in distal esophagus: association with gastroesophageal reflux. Indian J Gastroenterol. 2001;20:144-147.
28. Punia RS, Arya S, Mohan H, Duseja A, Bal A. Spectrum of clinico-pathological changes in Barrett oesophagus. J Assoc Physicians India. 2006;54:187-189.
29. Bafandeh Y, Esmaili H, Aharizad S. Endoscopic and histologic findings in Iranian patients with heartburn. Indian J Gastroenterol. 2005;24:236-238.
30. Rezailashkajani M, Roshandel D, Shafaee S, Zali MR. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients. Eur J Gastroenterol Hepatol. 2007;19:499-506.
31. Azuma N, Endo T, Arimura Y, Motoya S, Itoh F, et al. Prevalence of Barrett esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett esophagus and esophageal adenocarcinoma in Japan. J Gastroenterol. 2000;35:583-592.
32. Fujiwara Y, Higuchi K, Shiba M, Watanabe T, Tominaga K, et al. Association between gastroesophageal flap valve, reflux esophagitis, Barrett epithelium, and atrophic gastritis assessed by endoscopy in Japanese patients. J Gastroenterol. 2003;38:533-539.
33. Kawano T, Kouzu T, Ohara S, Kusano M. The prevalence of Barrett mucosa in the Japanese [in Japanese with English abstract]. Gastroenterol Endosc. 2005;47:951-961.
34. Lee JI, Park H, Jung HY, Rhee PL, Song CW, Choi MG. Prevalence of Barrett esophagus in an urban Korean population: a multicenter study. J Gastroenterol. 2003;38:23-27.
35. Kim JH, Rhee PL, Lee JH, Lee H, Choi YS, et al. Prevalence and risk factors of Barrett esophagus in Korea. J Gastroenterol Hepatol. 2007;22:908-912.
36. Choi DW, Oh SN, Baek SJ, Ahn SH, Chang YJ, et al. Endoscopically observed lower esophageal capillary patterns. Korean J Intern Med. 2002;17:245-248.
37. Kim JY, Kim YS, Jung MK, Park JJ, Kang DH, et al. Prevalence of Barrett esophagus in Korea. J Gastroenterol Hepatol. 2005;20:633-636.
38. Rosaida MS, Goh KL. Gastro-oesophageal reflux disease, reflux oesophagitis and non-erosive reflux disease in a multiracial Asian population: a prospective, endoscopy based study. Eur J Gastroenterol Hepatol. 2004;16:495-501.
39. Gadour MO, Ayoola EA. Barrett oesophagus and oesophageal cancer in Saudi Arabia. Trop Gastroenterol. 1999;20:111-115.
40. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett oesophagitis and columnar metaplasia. Aliment Pharmacol Ther. 2004;20(suppl 5):40-47.
41. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, et al. The development and validation of an endoscopic grading system for Barrett esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392-1399.
42. Amano Y, Ishimura N, Furuta K, Takahashi Y, Chinuki D, et al. Which landmark results in a more consistent diagnosis of Barrett esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc. 2006;64:206-211.
43. The Japan Esophageal Society. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 10th ed. Tokyo, Japan: Kanehara Co.
44. Hoshihara Y, Kogure T, Yamamoto T, Hoshimoto M, Hoteya O. Endoscopic diagnosis of Barrett esophagus [in Japanese with English abstract]. Nippon Rinsho. 2005;63:1394-1398.
45. Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145-150.
46. de Carvalho CA. Sur l'angioarchitecture veineuse de la zone de transition oesophagogastrique et son interpretation fonctionnelle. Acta Anat. 1966;64: 125-162.
47. Noda T. Angioarchitectural study of esophageal varices. With special reference to variceal rupture. Virchows Arch A Pathol Anat Histopathol. 1984;404:381-392.
48. Vianna A, Hayes PC, Moscoso G, Driver M, Portmann B, et al. Normal venous circulation of the gastroesophageal junction. A route to understanding varices. Gastroenterology. 1987;93:876-889.
49. Kerkhof M, Steyerberg EW, Kusters JG, Kuipers EJ, Siersema PD. Predicting presence of intestinal metaplasia and dysplasia in columnar-lined esophagus: a multivariate analysis. Endoscopy. 2007;39:772-778.
50. Takubo K, Sasajima K, Yamashita K, Tanaka Y, Fujita K. Double muscularis mucosae in Barrett esophagus. Hum Pathol. 1991;22:1158-1161.
51. Takubo K, Nixon JM, Jass JR. Ducts of esophageal glands proper and Paneth cells in Barrett esophagus: frequency in biopsy specimens. Pathology. 1995;27: 315-317.
52. Long JD, Orlando RC. Esophageal submucosal glands: structure and function. Am J Gastroenterol. 1999;94:2818-2824.
53. Takubo K, Vieth M, Aryal G, Honma N, Sawabe M, et al. Islands of squamous epithelium and their surrounding mucosa in columnar-lined esophagus: a pathognomonic feature of Barrett esophagus? Hum Pathol. 2005;36:269-274.
54. Paris Workshop on Columnar Metaplasia in the Esophagus and the Esophagogastric Junction, Paris, France, December 11-12 2004. Endoscopy. 2005;37: 879-920.
55. Campos GM, DeMeester SR, Peters JH, Oberg S, Crookes PF, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg. 2001;136:1267-1273.
56. Conio M, Filiberti R, Blanchi S, Ferraris R, Marchi S, et al. Risk factors for Barrett esophagus: a case-control study. Int J Cancer. 2002;97:225-229.
57. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett esophagus. Dig Dis Sci. 2002;47:256-264.
58. Wakelin DE, Al-Mutawa T, Wendel C, Green C, Garewal HS, Fass R. A predictive model for length of Barrett esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc. 2003;58:350-355.
59. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97:1930-1936.
60. de Jonge PJ, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett esophagus. Am J Gastroenterol. 2006;101:1421-1429.
61. Amano K, Adachi K, Katsube T, Watanabe M, Kinoshita Y. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol. 2001;16:132-136.
62. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, et al. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol. 2001;16:969-975.
63. Singh V, Trikha B, Nain CK, Singh K, Vaiphei K. Epidemiology of Helicobacter pylori and peptic ulcet in India. J Gastroenterol Hepatol. 2002;17:659-665.
64. Brown LM, Thomas TL, Ma JL, Chang YS, You WC, et al. Helicobacter pylori infection in rural China: demographic, lifestyle and environmental factors. Int J Epidemiol. 2002;31:638-645.
65. Tan HJ, Rizal AM, Rosmadi MY, Goh KL. Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. J Gastroenterol Hepatol. 2005;20:589-594.
66. Jais M, Barua S. Seroprevalence of anti Helicobacter pylori IgG/IgA in asymptomatic population from Delhi. J Commun Dis. 2004;30:132-135.
67. Lin HY, Chuang CK, Lee HC, Chiu NC, Lin SP, Yeung CY. A seroepidemiologic study of Helicobacter pylori and hepatitis A virus infection in primary school students in Taipei. J Microbiol Immunol Infect. 2005;8:176-182.
68. Khan MA, Ghazi HO. Helicobacter pylori infection in asymptomatic subjects in Makkah, Saudi Arabia. J Pak Med Assoc. 2007;57:114-117.
69. Rajendra S, Ackroyd R, Robertson IK, Ho JJ, Karim N, Kutty KM. Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter. 2007;12:177-183.
70. Asaka M, Kimura T, Kudo M, Takeda H, Mitani S, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760-766.
71. Fujisawa T, Kumagai T, Akamatsu T, Kiyosawa K, Matsunaga Y. Changes in seroepidemiological pattern of Helicobacter pylori and hepatitis A virus over the last 20 years in Japan. Am J Gastroenterol. 1999;94:2094-2099.
72. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007;12:333-340.
73. Lee SY, Park HS, Yu SK, Sung IK, Jin CJ, et al. Decreasing prevalence of Helicobacter pylori infection: a 9-year observational study. Hepatogastroenterology. 2007;54:630-633.
74. Chen J, Bu XL, Wang QY, Hu PJ, Chen MH. Decreasing seroprevalence of Helicobacter pylori infection during 1993-2003 in Guangzhou, southern China. Helicobacter. 2007;12:164-169.
75. Vieth M, Masoud B, Meining A, Stolte M. Helicobacter pylori infection: protection against Barrett mucosa and neoplasia? Digestion. 2000;62:225-231.
76. Abe Y, Ohara S, Koike T, Sekine H, Iijima K, et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett esophagus in Japan. Am J Gastroenterol. 2004;99:1213-1221.
77. Zhang J, Chen XL, Wang KM, Guo XD, Zuo AL, Gong J. Relationship of gastric Helicobacter pylori infection to Barrett esophagus and gastro-esophageal reflux disease in Chinese. World J Gastroenterol. 2004;10:672-675.
78. Amano Y, Kushiyama Y, Yuki T, Takahashi Y, Chinuki D, et al. Predictors for squamous re-epithelialization of Barrett esophagus after endoscopic biopsy. J Gastroenterol Hepatol. 2007;22:901-907.
79. Chinuki D, Amano Y, Ishihara S, et al. REG Ia protein expression in Barrett esophagus. J Gastroenterol Hepatol. In press.
80. Loffeld RJ, van der Putten AB. Helicobacter pylori and gastro-oesophageal reflux disease: a cross-sectional epidemiological study. Neth J Med. 2004;62: 188-191.
81. Wani S, Sampliner RE, Weston AP, Mathur S, Hall M, et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett oesophagus. Aliment Pharmacol Ther. 2005;22:627-633.
82. Weston AP, Badr AS, Topaiovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett esophagus, Barrett dysplasia, and Barrett adenocarcinoma. Am J Gastroenterol. 2000;95:387-394.
83. Veldhuyzen van Zanten SJ, Thomson AB, Barkun AN, Armstrong D, Chiba N, et al. The prevalence of Barrett oesophagus in a cohort of 1040 Canadian primary care patients with uninvestigated dyspepsia undergoing prompt endoscopy. Aliment Pharmacol Ther. 2006;23:595-599.
84. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:884-887.
85. Yachida S, Saito D, Kozu T, Gotoda T, Inui T, et al. Endoscopically demonstrable esophageal changes after Helicobacter pylori eradication in patients with gastric disease. J Gastroenterol Hepatol. 2001;16:1346-1352.
86. Kokkola A, Sipponen P, Haapiainen R, Rautelin H, Karjalainen-Lindsberg ML, Puolakkainen P. Development of Barrett esophagus after 'spontaneous' healing of atrophic corpus gastritis. Helicobacter. 2003;8:590-593.
87. Vicari JJ, Peek RM, Falk GW, Goldblum JR, Easley KA, et al. The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 1998;115:50-57.
88. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, et al. An inverse relation between cag A+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588-590.
89. Clark GW. Effect of Helicobacter pylori infection in Barrett esophagus and the genesis of esophageal adenocarcinoma. World J Surg. 2003;27:994-998.
90. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett esophagus. Am J Gastroenterol. 2000;95:2206-2211.
91. Ackermark P, Kuipers EJ, Wolf C, Breumelhof R, Seidenrijk CA, et al. Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. Am J Gastroenterol. 2003;98: 1719-1724.
92. Ferrández A, Benito R, Arenas J, García-González MA, Sopeña F, et al. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett esophagus in a population with high H. pylori infection rate. BMC Gastroenterol. 2006;6:7.
93. Quddus MR, Henley JD, Sulaiman RA, et al. Helicobacter pylori infection and adenocarcinoma arising in Barrett esophagus. Hum Pathol. 1997;28:1007-1009.
94. Geoffrey WB, Clark GWB. Effect of Helicobacter pylori infection in Barrett esophagus and the genesis of esophageal adenocarcinoma. World J Surg. 2003;27:994-998.
95. Henihan RD, Stuart RC, Nolan N, Gorey TF, Hennessy TP, O'Morain CA. Barrett esophagus and the presence of Helicobacter pylori. Am J Gastroenterol. 1998;93:542-546.
96. Koike T, Ohara S, Inomata Y, Abe Y, Iijima K, Shimosegawa T. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan. Inflammopharmacology. 2007;15:61-64.
97. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol. 2006;4:398-407.
98. Amano Y, Kushiyama Y, Ishihara S, Yuki T, Miyaoka Y, et al. Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short-segment Barrett esophagus. Am J Gastroenterol. 2005;100:21-26.
99. Yuki T, Amano Y, Kushiyama Y, Takahashi Y, Ose T, et al. Evaluation of modified crystal violet chromoendoscopy procedure using new mucosal pit pattern classification for detection of Barrett dysplastic lesions. Dig Liver Dis. 2006;38: 296-300.
100. Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett esophagus. Gastrointest Endosc. 2001;53:559-565.
101. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett oesophagus. Gut. 2003;52:24-27.
102. Kara MA, Ennahachi M, Fockens P, ten Kate FJ, Bergman JJ. Detection and classification of the mucosal and vascular patterns (mucosal morphology) in Barrett esophagus by using narrow band imaging. Gastrointest Endosc. 2006;64:155-166.
103. Goda K, Tajiri H, Ikegami M, Urashima M, Nakayoshi T, Kaise M. Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett adenocarcinoma. Gastrointest Endosc. 2007;65:36-46.
104. Kara MA, Peters FP, Fockens P, ten Kate FJ, Bergman JJ. Endoscopic video-autofluorescence imaging followed by narrow band imaging for detecting early neoplasia in Barrett esophagus. Gastrointest Endosc. 2006;64:176-185.
105. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
106. Amano Y, Chinuki D, Yuki T, Takahashi Y, Ishimura N, et al. Efficacy of proton pump inhibitors for cellular proliferation and apoptosis in Barrett oesophagus with different mucin phenotypes. Aliment Pharmacol Ther. 2006;24(suppl 4):41-48.
107. Peters FT, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, et al. Endoscopic regression of Barrett oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45:489-494.
108. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther. 1999;13:1205-1209.
109. Srinivasan R, Katz PO, Ramakrishnan A, Katzka DA, Vela MF, Castell DO. Maximal acid reflux control for Barrett oesophagus: feasible and effective. Aliment Pharmacol Ther. 2001;15:519-524.
110. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett oesophagus: a ptospective study. Lancet Oncol. 2005;6:945-952.
111. Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia- adenocarcinoma sequence. Cancer Res. 2006;66:4975-4982.
112. Triadafilopoulos G, Kaur B, Sood S, Traxler B, Levine D, Weston A. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett oesophagus. Aliment Pharmacol Ther. 2006;23:997-1005.
113. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis. 2005;26:565-570.
114. Lanas A, Ortego J, Sopeña F, Alcedo J, Barrio E, et al. Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett oesophagus. Aliment Pharmacol Ther. 2007;26:913-923.
115. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, et al. Secondary chemoprevention of Barrett esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007;99:545-557.